Maa: Uusi-Seelanti
Kieli: englanti
Lähde: Medsafe (Medicines Safety Authority)
Nicotine 16.6mg (20cm² patch delivers 10mg/16hours.);
Johnson & Johnson (New Zealand) Limited
Nicotine 16.6 mg (20cm² patch delivers 10mg/16hours.)
10mg/16hours
Transdermal patch
Active: Nicotine 16.6mg (20cm² patch delivers 10mg/16hours.)
Individual wrap, 7x20cm� patches, 7 patches
General sale
General sale
Siegfried Ltd
Package - Contents - Shelf Life: Individual wrap, 7x20cm? patches - 7 patches - 36 months from date of manufacture stored at or below 25°C
1991-06-28
HOME | CONSUMERS | HEALTH PROFESSIONALS | REGULATORY | OTHER | HOT TOPICS | SEARCH DATA SHEET NICORETTE ® PATCH 5MG/16H, 10MG/16H, 15MG/16H PRESENTATION Nicorette Patch is a transdermal delivery system for topical application, available in sizes of 30, 20 and 10 cm 2 each containing 0.83 mg/cm 2 of nicotine, releasing 15 mg, 10 mg and 5 mg respectively over 16 hours. Each patch is rectangular in shape and comprises 3 distinct layers; an outer beige matt finish backing layer, a patterned silvery middle layer and an inner clear release liner, which is removed prior to use. Each patch is packaged in a heat sealed multilaminate sachet. USES ACTIONS Pharmacotherapeutic group: Drug for treatment of addiction. ATC code: N07B A01 Abrupt cessation of the use of tobacco-containing products following a prolonged period of daily use results in a characteristic withdrawal syndrome that includes four or more of the following: dysphoria or depressed mood; insomnia; irritability, frustration or anger; anxiety; difficulty concentrating, restlessness or impatience; decreased heart rate; and increased appetite or weight gain. Nicotine craving, which is recognised as a clinically relevant symptom, is also an important element in nicotine withdrawal. Clinical studies have shown that nicotine replacement products can help smokers abstain from smoking. PHARMACOKINETICS GENERAL PHARMACOKINETIC PROPERTIES OF NICOTINE The volume of distribution following i.v. administration of nicotine is about 2 to 3 L/kg. Plasma protein binding of nicotine is <5%. Therefore, changes in nicotine binding from use of concomitant drugs or alterations of plasma proteins by disease states would not be expected to have significant effects on nicotine kinetics. The average plasma clearance following intravenous administration of nicotine is about 70 L/hour and the terminal half-life approximately 2 hours. The major eliminat Lue koko asiakirja